Efficacy and Safety of Recombinant Human Erythropoietin Combined with All-Trans Retinoic Acid and Testosterone Undecanoate in Treating Anemia in Patients with Lower-Risk Myelodysplastic Syndromes: A Prospective, Multicenter, Double-Blind, Randomized Controlled Clinical Study

开始日期2025-09-30

申办/合作机构

浙江大学医学院附属第二医院（浙江省第二医院）

[+1]

NCT06188767

/ RecruitingN/A

Long-term Effects of Anabolic Androgenic Steroids on Muscle Growth Potential: Testosterone-induced Muscle Memory and Underlying Mechanisms

The purpose of this project is to investigate underlying mechanisms of testosterone- and resistance training-induced muscle hypertrophy and muscle memory in humans.

开始日期2025-04-01

申办/合作机构

University of Copenhagen

NCT06082817

/ Not yet recruiting临床2期IIT

An Open-Label Pilot Study of the Pharmacokinetics and Safety of 50 Mg Oral Testosterone Undecanoate (Kyzatrex) in Menopausal Women with Low Testosterone and Hypoactive Sexual Desire Disorder

This is an unblinded study to be conducted at a single research center, San Diego Sexual Medicine. Eligible subjects will receive 50 mg capsules of Kyzatrax® to be taken orally daily over a 3-month period. Multiple blood samples will be taken at baseline and on days 7, 28 and 56 to assess safety and pharmacokinetics of the testosterone. After the informed consent is signed and for up to 14 days after the last dose of study drug, participants will have serial blood samples collected in addition to other routine study procedures (e.g. vital signs measured, adverse events assessed, validated outcome scales completed).

开始日期2025-01-01

申办/合作机构-

100 项与十一酸睾酮相关的临床结果

登录后查看更多信息

100 项与十一酸睾酮相关的转化医学

登录后查看更多信息

100 项与十一酸睾酮相关的专利（医药）

登录后查看更多信息

791

项与十一酸睾酮相关的文献（医药）

2025-09-01·CLINICA CHIMICA ACTA

Recognition, prevalence and prevention of falsely high serum testosterone concentrations in testosterone gel users

Article

作者: Wiepjes, C M ; den Heijer, M ; Heijboer, A C ; Stangl, T A

BACKGROUND:

Contamination of blood samples by application of testosterone gel near the venipuncture site may be a cause of falsely elevated serum testosterone (T) concentrations. We hypothesized that measuring estradiol (E) and calculating the T/E ratio could give a biochemical clue for contamination because skin-originating testosterone will not be aromatized to estradiol. We assessed the prevalence of abnormal T/E ratio in gel users and tested our hypothesis in 10 volunteers.

METHODS:

Retrospective study involving 277 transmasculine persons, using testosterone treatment (180 gel and 111 testosterone undecanoate (TU) injection users). Testosterone, estradiol and T/E ratio were assessed. In 10 volunteers we compared T/E ratios between gel-exposed and unexposed arms where the gel was applied on the venipuncture site or distal of the venipuncture site.

RESULTS:

Using an upper limit of 0.60 for the T/E ratio, we found 12 samples (7.3 %, 95%CI 3.8-12.3 %) with an elevated T/E ratio in the gel group and one (0.9 %, 95%CI 0.0-4.9 %) in the TU group. In the explorative study application of testosterone gel on the venipuncture site was associated with a higher mean (range) testosterone concentration (33. 2 (17.0-50.0) vs 14.2 (7.2-21.0) nmol/L and a higher mean (range) T/E ratio (0.55(0.29-0.66) vs 0.23(0.18-0.29)) compared to samples taken from unexposed arms. This difference between arms could not be reproduced when applying gel distal to the venipuncture site.

CONCLUSION:

Testosterone contamination of blood samples is rather common among testosterone gel users, and can be recognized by an increased T/E ratio. To prevent testosterone contamination, application of testosterone gel especially at the venipuncture site should be avoided. Clinicians and laboratory specialists should stay attentive to this common form of contamination and instruct patients accordingly.

2025-09-01·DRUG METABOLISM AND DISPOSITION

Curcumin enhances the oral bioavailability of testosterone by inhibiting its intestinal metabolism

Article

作者: Prasad, Bhagwat ; Singh, Dilip Kumar ; Shaffer, Griffin ; Bachhav, Namrata ; Amory, John K

Hypogonadism, characterized by low testosterone blood levels, affects 3%-5% of males worldwide. Oral testosterone undecanoate (TU) is emerging as a key route of administration due to its better ease of administration; however, it suffers from variable pharmacokinetics and pharmacodynamics. The variability is majorly attributed to intestinal glucuronidation of testosterone to its hydrophilic metabolite, testosterone glucuronide (TG), formed by the polymorphic uridine 5'-diphospho-glucuronosyltransferase 2B17 (UGT2B17). This study investigated the potential of curcumin, as a UGT2B17 inhibitor, to enhance TU bioavailability using a series of in vitro and in vivo studies. In human intestinal microsomes, curcumin inhibited UGT2B17 with an IC₅₀ of 58 μM. In LS180 cells, a human intestinal cell line, curcumin reduced TG formation dose-dependently at 10, 25, and 100 μM, and also inhibited the formation of androstenedione at 100 μM. In primary human enterocytes, curcumin (100 μM) significantly reduced TG and androstenedione formation by ∼50%. A pilot crossover clinical study compared testosterone pharmacokinetics when TU was coadministered with curcumin in men with experimental hypogonadism. The plasma concentration-time area under the curve (AUC_1-6h) and the peak plasma concentration (C_max) for testosterone, representing the absorption phase, significantly increased by 50% and 80%, respectively, when TU was administered with curcumin. These findings suggest that curcumin, a UGT2B17 inhibitor, has the potential to enhance the bioavailability of oral TU. Further clinical investigations with higher doses of curcumin and with other UGT2B17 inhibitors in diverse populations are warranted to validate the UGT2B17 inhibition approach for enhancing oral testosterone replacement therapy. SIGNIFICANCE STATEMENT: Hypogonadism affects a significant portion of the male population. Oral testosterone undecanoate is recommended to treat hypogonadism, but shows variable pharmacokinetics and pharmacodynamics. This study evaluated curcumin as a potential enhancer of testosterone undecanoate bioavailability by inhibiting intestinal UGT2B17, the key enzyme mediating testosterone glucuronidation. In vitro and pilot clinical studies showed that curcumin can inhibit testosterone metabolism and enhance its systemic levels. These findings suggest that UGT2B17 inhibition by curcumin or other UGT2B17 inhibitors could be a promising approach to improve oral testosterone bioavailability.

2025-08-01·Drug Testing and Analysis

Detection of Oral Testosterone Undecanoate Administration in UGT2B17 del/del and del/ins Individuals. Part I: Urinary Steroid Profile and IRMS Markers

Article

作者: Alechaga, Élida ; Ventura, Rosa ; Okano, Masato ; Monfort, Núria ; Shiomura, Sho ; Coll, Sergi ; Bressan, Claudia

ABSTRACT:

The detection of endogenous anabolic androgenic steroids misuse in Asian population using the Steroidal Module of the Athlete Biological Passport (ABP) is a challenge due to the high prevalence of UGT2B17 gene deletion polymorphism and low levels of testosterone (T) glucuronide. In this study, the capabilities of different approaches based on urine analysis for detecting oral T undecanoate administration were evaluated in 13 Asian volunteers, including 11 subjects with del/del genotype and 2 subjects with del/ins genotype. In this part of the work, the effect on the urinary steroid profile (SP) and the isotope ratio mass spectrometry (IRMS) markers were studied. Results showed that the 5α‐androstane‐3α,17β‐diol/epitestosterone ratio is the most sensitive marker of the SP to detect oral T administration in Asian volunteers. All urines that led to suspicious urinary SP were concluded IRMS positive. However, for some subjects, the ABP Steroidal Module was unable to identify suspicious samples that were still detectable by IRMS. Positive IRMS samples were detected up to 24 h (n = 9), 36 h (n = 3), or 48 h (n = 1) after oral administration. Overall, the urinary SP together with IRMS allowed the detection of T administration in Asian volunteers. However, the detection windows are short, as reported for oral T administration in Caucasian volunteers. These findings highlight the need of implementing additional markers in the Steroidal Module of ABP that could enlarge detection windows.

161

项与十一酸睾酮相关的新闻（医药）

2025-09-10

·EndPoints

Hims expands into hormone health with men's testosterone treatment

Hims & Hers is launching men’s hormone health services, the company said Wednesday. To start, Hims will offer compounded enclomiphene, a treatment used to help men with low testosterone by inhibiting estrogen production. Next year, it plans to offer injectable and oral testosterone. It’s exclusively working with Marius Pharmaceuticals, which makes the oral testosterone medication Kyzatrex, to offer a Hims-labeled oral testosterone. With the launch of testosterone treatments, Hims joins a growing group of telehealth companies, including Hone Health, Henry Meds and independent clinics that have been prescribing testosterone online over the past few years. During Hims’ second-quarter earnings call, CEO Andrew Dudum highlighted hormonal health as one of the ways in which the company plans to grow its business to $6.5 billion in revenue by 2030, along with lab testing and international expansion. The new offering is the first time at-home lab testing is included in the launch of a new specialty. “The interrelationships between sexual health, obesity, low testosterone, are really profound, and we’re marching towards really holistic care that is comprehensive,” Peter Stahl, head of men’s health at Hims told Endpoints News. “Adding testosterone into our portfolio improves our ability to address some of the other really important conditions that we currently treat.” The expansion in 2026 into offering testosterone will also mark the first time Hims will offer a controlled substance. It’s listed as a schedule III drug by the government, meaning its distribution is limited because of the risk of abuse. “We’ve systematically built up a clinical quality and safety program over many years that I think is robust enough to support safe, effective and evidence-based controlled substance prescribing now,” Stahl said. Because it’s a controlled substance, it can often be hard to get prescribed testosterone during a traditional doctor’s office visit, he said. (This story is from our Health Tech newsletter. If you’d like to sign up, just click here .)

2025-09-10

·Firstwordpharma

Hims & Hers Health expands into testosterone therapy after Novo Nordisk breakup

Telehealth company Hims & Hers Health announced Wednesday that it is launching treatment for low testosterone. Effective immediately, providers on the Hims platform can prescribe personalised doses of a compounded version of the selective estrogen receptor modulator enclomiphene, either alone or combined with the erectile dysfunction medication tadalafil, for men experiencing sexual symptoms. Beginning next year, Hims will also offer Kyzatrex (testosterone undecanoate), an FDA-approved oral testosterone replacement therapy from Marius Pharmaceuticals.According to Hims, an estimated 20 million men in the US have low testosterone — a condition associated with fatigue, depression, reduced libido and an increased risk of serious health issues like heart disease, diabetes and cancer. Despite these risks, most men with low testosterone go untreated. "Low testosterone care has been stuck in the past, stigmatised, expensive and inaccessible for most men," said Andrew Dudum, founder and CEO of Hims & Hers. He added that the company aims to make treatment easily accessible and tailored to each patient's needs. To begin treatment, patients take an at-home blood test. Once results are available — typically within a few days — patients work with their provider to choose the best treatment plan, which may include ongoing at-home lab testing and provider check-ins, round-the-clock access to a care team, medication adjustments and educational resources available through the Hims app. Enclomiphene helps the body resume natural testosterone production without affecting fertility, according to Hims. The company also states that Kyzatrex restores testosterone levels in up to 96% of men, doubling free testosterone while maintaining a low side effect profile. "Marius developed Kyzatrex to modernise testosterone replacement therapy with an oral treatment backed by rigorous science and FDA approval," said Shalin Shah, CEO of Marius Pharmaceuticals. "Partnering with Hims & Hers allows us to bring this innovation to scale," he continued, adding that Hims' platform will help the drug reach millions of consumers. In addition to oral therapies, Hims plans to introduce injectable testosterone treatments through its digital platform in 2026.The expansion could serve as a new revenue-generating product line for the company as it distances itself from the regulatory uncertainties surrounding compounded weight-loss drugs. Hims took a huge financial hit after the FDA removed semaglutide from its shortage list, causing a sharp decline in sales of its compounded weight-loss offerings. It has also faced scrutiny from the FTC over its subscription practices and is battling investor lawsuits claiming the company misrepresented its financial status following its break-up with Novo Nordisk.

并购

2025-08-18

·EINPresswire

Male Hypogonadism Market to Reach USD 5.32 Billion by 2032, Growing at a CAGR of 4.8% To Forecast 2025-2032

Male Hypogonadism revenue is expected to grow at a CAGR of 4.8% from 2025 to 2032, reaching nearly USD 5.32 Bn. by 2032. Advancements in testosterone therapy and diagnostics are reshaping the male hypogonadism market, bringing health and vitality back to millions.” — Dharati Raut SAVANNAH, GA, UNITED STATES, August 18, 2025 / EINPresswire.com / -- Stellar Market Research examines the growth rate of the Male Hypogonadism Market during the forecasted period 2025-2032 The Male Hypogonadism Market is projected to grow at a CAGR of approximately 4.8% over the forecast period. The Male Hypogonadism Market was valued at USD 3.65 billion in 2024 and is expected to reach USD 5.32 billion by 2032. More old people, higher rates of obesity, better tests, new testosterone treatments, more people knowing about it, growth in telehealth, and better access to health care are all major reasons driving the Male Hypogonadism market. Male Hypogonadism Market Overview The male hypogonadism market deals with finding and treating this issue. It grows as more people get old, more get long-term health problems, and more become aware of it. Better tools for finding the issue and new ways to treat it, like gels, shots, and under-skin devices, give more choices for care. More people can now get health care, especially in new markets, and things like health care from home help the market grow. The big companies in this area work on making treatments that are safe and fit the person. All in all, this market looks set to grow steadily, helped by new ideas and a stronger focus on the health and life quality of men. To know the most attractive segments, click here for a free sample of the report: https://www.stellarmr.com/report/req_sample/Male-Hypogonadism-Market/1780 Male Hypogonadism Market Dynamics Drivers Expansion of Healthcare Infrastructure Growing health care setups in new markets, like Asia-Pacific, Middle East, and Latin America, are helping more men get checked and treated for low hormone issues. Money put into online health services, AI-based tests, better insurance, and new government rules are making care cheaper and reaching more people. These steps help the market grow by finding health problems sooner, making care fit each person, and spreading treatments wider in areas that didn't have much help before. Innovation in Treatment Modalities New forms of testosterone fix (TRT) are now out like FDA-ok'd pills (Jatenzo, TLANDO), nose gels (Natesto), and new skin gels and shots. These types give safer, easier, and one-of-a-kind care that make it better for men to keep up. New updates on FDA labels take away heart health risk alerts and this helps more men get TRT. This makes TRT more open and it works better for men with low hormone levels. Advances in Diagnostic Technologies Better ways to find out if a man has low testosterone now exist. Quick auto tests for free testosterone, more home blood and spit kits, and new point-of-care tools are here. Better scans like shear wave elastography and MRI make results more exact. These new things help find the issue sooner, with more right results, make it easy to get help, and lift the number of people getting treated. This helps the market grow by making it easier for people to take care of their health early on and reach more people in places with less help. Restrain Lack of Awareness and Social Stigma Many men with low hormone levels are not diagnosed because their signs mix with old age and there is a bad view on hormone help and being 'manly.' Efforts to spread the word, online health help, and doctor education are making it easier to break these walls. Still, bad views keep many from getting a diagnosis and treatment, holding back market growth as lots of men don't seek the care they need soon enough. Innovations and Developments Technological innovation is a key factor propelling the Male Hypogonadism Market forward. Notable advancements include: Ulo, a telehealth startup, gives custom at-home testosterone help. They offer lab checks, online talks, and send out monthly care from $159. This makes it easy, safe, and easy to reach with steady checks. In February 2025, the FDA changed the tags on testosterone items. They took off heart risk notes due to new test data and put in blood pressure notes. This made things clearer about safety and lifted trust for users and providers. Male Hypogonadism Market Segmentation By Disease Type By Disease Type, the Male Hypogonadism Market is further segmented into Klinefelter's Syndrome, Kallmann Syndrome, Pituitary Disorders, and Others. Klinefelter Syndrome dominates the male hypogonadism market since it shows up more (1 in 500 males), has better tests, and has new man hormone fixes. It made the most money in 2024, and the market will likely get much bigger by 2034. This growth comes from more people knowing about it and better ways to treat it. Male Hypogonadism Market Regional Analysis North America: North America dominates the Male Hypogonadism Market due its top-notch health care set-up, high knowing about the issue, strong insurance help, solid work in research and growth, good laws, and more use of telehealth. All these points make getting a check, getting to treatment, and new ways to treat better. Europe: Europe is number two in the Male Hypogonadism Market. This is due to good health care, more people knowing about it, lower prices from biosimilar use, helpful rules, and big steps in main places. For example, Germany has special treatment spots and the UK quickly says yes to TRT, making it easy and cheap for more people. Asia-Pacific: Asia-Pacific is third in the Male Hypogonadism Market due to fast health care upgrades, aid from the government in China, Japan, and India, more knowing about the issue, more ways to get care, and the rising need from a growing middle class. Recent Developments: Clarus Therapeutics got a lot of talk with its pill form of testosterone help, JATENZO ® , and Marius Pharmaceuticals grew big by using special doctor plans. Both teams lead the way in easy, pill-based TRT help. In September 2024, WellSync teamed up with Marius Pharmaceuticals to give out KYZATREX (a type of pill testosterone) on its web care site, making it easier for patients to get to testosterone change help. To know the most attractive segments, click here for a free sample of the report: https://www.stellarmr.com/report/req_sample/Male-Hypogonadism-Market/1780 Male Hypogonadism Market Competitive Landscape The global and regional players in the Male Hypogonadism Market concentrate on developing and enhancing their capabilities, resulting in fierce competition. Notable players include: Endo International Plc (Ireland) AbbVie Inc (United States) Pfizer Inc (United States) Teva Pharmaceutical Industries Ltd (Israel) Allergan Plc (Ireland) IBSA Institut Biochimque SA (Switzerland) Eli Lilly & Company Ltd (United States) Ferring International Center SA (Switzerland) Merck & Co. Inc (United States) Bayer AG (Germany) Related Reports: PEEK Implants Market: https://www.stellarmr.com/report/pEEK-implants-market/2742 Medical Device Design Development Services Market: https://www.stellarmr.com/report/medical-device-design-development-services-market/2741 Iron Deficiency Anemia Therapy Market: https://www.stellarmr.com/report/iron-deficiency-anemia-therapy-market/2740 North America Aesthetic Medical Devices Market: https://www.stellarmr.com/report/north-america-aesthetic-medical-devices-market/2719 Veterinary Excipients Market: https://www.stellarmr.com/report/veterinary-excipients-market/2716 About Stellar Market Research: Stellar Market Research is a multifaceted market research and consulting company with professionals from several industries. Some of the industries we cover include medical devices, pharmaceutical manufacturers, science and engineering, electronic components, industrial equipment, technology and communication, cars and automobiles, chemical products and substances, general merchandise, beverages, personal care, and automated systems. To mention a few, we provide market-verified industry estimations, technical trend analysis, crucial market research, strategic advice, competition analysis, production and demand analysis, and client impact studies. Contact Stellar Market Research: S.no.8, h.no. 4-8 Pl.7/4, Kothrud, Pinnac Memories Fl. No. 3, Kothrud, Pune, Pune, Maharashtra, 411029 sales@stellarmr.com Lumawant Godage Stellar Market Research + +91 9607365656 email us here Visit us on social media: LinkedIn Instagram X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

100 项与十一酸睾酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D06087	十一酸睾酮	G03BA03	DB13946

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
低睾酮水平	美国	Endo Operations Ltd.	2014-03-05
性腺机能减退	澳大利亚	Bayer Australia Ltd.	2005-10-26

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
睾酮缺乏	申请上市	加拿大	Marius Pharmaceuticals LLC	2024-07-30
无睾症	临床3期	美国	Clarus Therapeutics, Inc.	2011-07-01
无睾症	临床3期	德国	Clarus Therapeutics, Inc.	2011-07-01
先天性睾丸发育不全综合征	临床3期	美国	Endo Pharmaceuticals, Inc.	2006-03-01
多发性内分泌瘤病	临床3期	美国	Endo Pharmaceuticals, Inc.	2006-03-01
继发性睾丸衰竭	临床3期	美国	Endo Pharmaceuticals, Inc.	2006-03-01
慢性肾病	临床2期	美国	Clarus Therapeutics, Inc.	2022-03-15
转移性去势抵抗性前列腺癌	临床2期	美国	Clarus Therapeutics, Inc.	2022-03-07

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04456296 (CTgov)	临床4期	继发性睾丸衰竭 \| 无睾症	673	AVEED (AVEED® (Testosterone Undecanoate Injection))	網繭積淵膚顧範糧廠夢(醖範醖鹹獵憲遞鬱鬱製) = 鏇簾網齋構簾願窪構壓鑰餘襯願衊夢築廠鏇廠 (窪廠觸觸糧遞獵壓觸鑰, 選鹽鑰醖夢製遞淵餘獵 ~ 醖願獵顧鬱衊鑰齋夢蓋) 更多	-	2025-03-14
NCT04456296 (CTgov)	临床4期	继发性睾丸衰竭 \| 无睾症	673	FORTESTA (FORTESTA® (Testosterone Gel))	網繭積淵膚顧範糧廠夢(醖範醖鹹獵憲遞鬱鬱製) = 鹽醖遞獵齋願憲廠願鏇鑰餘襯願衊夢築廠鏇廠 (窪廠觸觸糧遞獵壓觸鑰, 選糧壓淵繭顧鬱顧鏇夢 ~ 遞繭鑰蓋鏇觸餘顧繭鹽) 更多	-	2025-03-14
AUA2024	临床3期	多发性内分泌瘤病	325	Oral Testosterone Undecanoate (316 mg BID)	廠憲糧製構鬱蓋簾鑰廠(繭構齋蓋築繭糧艱餘築) = 鬱廠積衊廠窪窪艱窪顧網鏇構衊廠醖艱獵膚觸 (艱鹹糧顧築網範憲餘遞 )	积极	2024-05-01
NCT03198728 \| NCT04467697 (Pubmed)	临床3期	多发性内分泌瘤病 \| 无睾症	155	KYZATREX	憲膚鬱艱範鬱選選鑰鑰(獵鹽範夢積顧鹹廠願壓) = hypertension 憲獵壓膚鏇構衊鬱獵衊 (顧糧鏇襯膚膚鬱範簾鏇 ) 更多	-	2024-04-10
NCT04983940 (CTgov)	临床4期	睾酮缺乏	41	Jatenzo	夢衊遞壓壓齋構築壓積(齋願鹽鹹鹽醖齋選構衊) = 醖願淵網鬱鹽餘鬱構鏇糧簾醖壓積艱廠艱醖願 (艱獵選膚範觸願窪鏇艱, 鏇範壓製廠繭製簾鹽膚 ~ 餘積蓋鬱憲淵艱簾範餘) 更多	-	2023-12-14
NCT03198728 (###DELETE, CTgov)	临床3期	无睾症	314	AndroGel (Andro-gel™ Treated)	淵淵鑰齋願遞窪醖願鬱 = 衊積壓鹹範積積繭觸淵餘夢積膚願廠網繭壓獵 (醖醖鏇觸夢鏇觸選衊糧, 構齋鹹範憲積壓醖衊淵 ~ 築構衊遞繭窪衊製繭鹽) 更多	-	2023-06-28
NCT03198728 (###DELETE, CTgov)	临床3期	无睾症	314	SOV2012-F1 (SOV2012-F1-Treated)	襯鹹選齋選築鏇顧顧鹽(製壓繭廠網夢衊簾繭壓) = 餘觸鑰艱製願積範壓齋選顧遞築鑰製網膚蓋觸 (醖遞範襯夢憲鹹窪膚鏇, 選獵遞願壓壓鏇鏇築衊 ~ 顧繭壓膚範鬱遞觸遞糧) 更多	-	2023-06-28
NCT04120363 (OPS II, CTgov)	临床4期	睡眠	34	Testosterone undecanoate (Testosterone)	糧鏇鹹淵製壓願顧醖獵(鹹顧鹹選衊壓窪鹽簾壓) = 衊膚壓遞夢鹹鏇窪淵淵選觸蓋鹽壓範築鹽淵顧 (壓鹽遞鏇鑰醖鹹壓襯窪, 2.01) 更多	-	2022-10-07
NCT04120363 (OPS II, CTgov)	临床4期	睡眠	34	Sesame Oil (Placebo)	糧鏇鹹淵製壓願顧醖獵(鹹顧鹹選衊壓窪鹽簾壓) = 憲簾遞膚餘窪醖製醖淵選觸蓋鹽壓範築鹽淵顧 (壓鹽遞鏇鑰醖鹹壓襯窪, 1.94) 更多	-	2022-10-07
AUA2022	临床4期	-	-	Jatenzo®	築窪範製憲鏇蓋膚憲顧(築選鏇齋艱餘廠夢鑰網) = 壓簾積遞艱願淵壓築膚糧簾簾構簾遞壓齋蓋鹽 (鏇簾壓窪網艱鬱觸構鬱 )	-	2022-05-01
NCT03242590 (Pubmed \| Andrology) 人工标引	临床3期	无睾症	95	testosterone	築艱夢醖醖積齋範膚鑰(積遞襯襯積齋膚糧壓衊) = 窪獵廠構築鹹廠鬱顧製壓鏇醖膚衊廠鹽廠糧鏇 (網艱願糧餘網窪簾艱齋, 72 ~ 88)	积极	2022-01-07
Pubmed \| J Clin Hypertens (Greenwich)	N/A	多发性内分泌瘤病	155	Kyzatrex™	製夢淵衊遞網艱鹹鹽鹽(憲衊範醖窪獵膚築網築) = 蓋構構構夢願簾顧糧窪積鹽壓艱餘艱獵憲壓糧 (夢鏇鹹築鹽鏇餘鏇選餘, 0.3 ~ 3.1)	-	2021-07-01
NCT03868059 (Pubmed \| J Cardiovasc Pharmacol Ther)	临床3期	多发性内分泌瘤病	138	TLANDO™ 225 mg twice daily	膚網構憲觸積顧糧窪繭(憲範廠膚艱憲艱憲膚繭) = 積蓋鹽憲選積遞遞網淵鏇夢製遞繭壓衊醖夢鏇 (願積壓餘鏇願淵構遞構 ) 更多	-	2021-06-30